AB 725 establishes a standalone regulatory chapter for source plasma donation centers in California. It authorizes facilities (distinct from licensed blood banks) to collect source plasma by plasmapheresis, to compensate donors, and requires those facilities to obtain a license from the State Department of Public Health which may inspect, suspend, or revoke licenses for violations.
The bill layers operational rules—staffing, donor screening and testing, photographic ID for paid donors, a medical director requirement, and an administrative fee regime that deposits license fees into the Clinical Laboratory Improvement Fund—onto an activity that was previously regulated differently or not at all at the state level. It also creates narrow liability protections for inadvertent HIV test disclosures and specific duties for local health officers when a donor tests reactive for HIV, including a record‑expungement obligation after notification efforts conclude.
At a Glance
What It Does
Creates Chapter 4.05 in the Health and Safety Code to authorize, license, and regulate source plasma donation centers; allows paid donor compensation; requires donor screening, testing, and informed consent; gives the Department of Public Health inspection and enforcement powers and sets misdemeanor penalties for violations.
Who It Affects
For‑profit and nonprofit operators that collect source plasma, manufacturers that use source plasma as input, the State Department of Public Health and local health officers who must inspect and handle certain donor records, clinical laboratory personnel, and donors (including adult consent and ID rules for paid donors).
Why It Matters
The bill creates a distinct California regulatory track for commercial plasma collection, aligning state oversight with federal testing requirements but also changing who regulates what, how fees are funded, and how donor privacy and notification are handled—issues that affect supply chains, compliance programs, and public‑health workflows.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 725 sets up a separate statutory framework for collection centers that obtain source plasma—the liquid portion of blood collected by plasmapheresis for manufacturing plasma‑derived products. The definition section draws lines that matter: the law covers plasmapheresis collections intended for further manufacturing and explicitly excludes single‑donor plasma products intended for direct intravenous use.
It also identifies roles such as a required medical director and a substitute medical director and references the National Donor Deferral Registry as part of the screening ecosystem.
On donations, the bill allows facilities to pay donors and requires additional front‑end controls for paid donors, including photographic identification. It also requires FDA‑recognized donor history questionnaires, informed consent about plasmapheresis risks, written notice that donations will be tested for transfusion‑transmitted infections, and that positive results may lead to deferral and placement on the donor‑deferral registry.
The statute creates a process for disclosing reactive HIV test results to local health officers when the center’s attempts to reach a donor fail, and then requires the local health officer to expunge records obtained in that process once notification efforts are complete. The text includes a limited liability shield for inadvertent HIV test disclosures by public entities or centers.Operationally, AB 725 permits a broader set of personnel to perform predonation screening and venipuncture—licensed and certain unlicensed staff subject to education, training, and supervision rules—with a licensed clinician responsible for reviewing work that federal GMP rules require reviewed.
It allows centers to run under general supervision rather than requiring a physician to be physically present, and permits delegation of supervision duties to a registered nurse while leaving ultimate responsibility with the physician.The licensing and enforcement mechanics are explicit. The Department must develop an application form and set fees that cover the cost of administering the chapter; fees are deposited into the Clinical Laboratory Improvement Fund.
If the Department does not act within 60 days, an application is deemed approved. Licenses must be amended when medical directors change; failure to name a new permanent medical director within prescribed timelines triggers automatic revocation.
The Department has on‑site inspection, record‑copying, and evidence‑collection authority, may suspend or revoke licenses under administrative procedures, may adopt implementing regulations, and violations are a misdemeanor with modest fines or jail time. The bill also creates narrow clinical‑testing exemptions (for a single total protein test using a digital refractometer) and clarifies that source plasma procurement and distribution constitutes a service rather than a sale.
The Five Things You Need to Know
If the Department of Public Health does not issue a license or refuse it in writing within 60 days of application filing, the application is deemed approved and a license is issued.
The bill expressly permits paid donations and requires paid donors to present photographic government identification (e.g.
DMV ID) before being accepted.
A wide range of personnel—licensed clinical lab bioanalysts, registered nurses, vocational nurses, blood donor phlebotomists, and designated source plasma donor phlebotomists—may perform venipuncture and skin puncture under general supervision; a physician need not be on‑site and may delegate supervision to an RN.
When a donor has a reactive HIV antibody result and the center cannot locate the donor, the center may disclose test results to a local health officer (without civil or criminal liability); after the health officer’s notification efforts conclude, all records obtained or maintained under that disclosure must be expunged.
Licensing fees must cover administration costs and be deposited into the Clinical Laboratory Improvement Fund; licenses expire after 12 months, renewal requires filing at least 10 days before expiration, and failure to timely renew leads to license expiration.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — California Source Plasma Donation Centers Act
This is the bill’s formal name; it signals the Legislature’s intent to treat source plasma collection as a distinct regulatory category rather than folding it entirely into existing blood bank law. Practically, the short title matters when regulations, contracts, or internal compliance documents reference the statute.
Clinical Laboratory Improvement Fund: fee scope and segregation
The amendment directs all fees from the new source plasma licensing chapter into the Clinical Laboratory Improvement Fund and requires interest earnings to remain in the fund. It also mandates that fees collected be expended only to administer their respective chapters once the Legislature appropriates the funds. For compliance teams, that creates a dedicated funding path for regulation—but actual department spending requires legislative appropriation, so operational funding is politically mediated rather than automatic.
Exemption from blood bank depository rules
This short amendment removes licensed source plasma donation centers from the statutory definition of blood bank depositories and the sole‑responsibility rules that attach to them. The practical effect: operators will not be treated as traditional blood bank depositories subject to those particular obligations, and regulators and counsel should not assume blood bank depository procedures apply automatically to source plasma centers.
Key definitional boundaries: what is 'source plasma' and who counts as a provider
The definitions carve out a narrow regulatory scope—covering plasmapheresis collections intended for manufacturing feedstock and excluding single‑donor IV plasma products—while importing constructs like a medical director, substitute director, and the National Donor Deferral Registry. These choices determine which facilities must license and which federal or state lab rules apply, and they anchor the supervision and recordkeeping obligations that follow.
Donor eligibility, payment, testing, disclosure, and record rules
This article authorizes compensation and layers donor protections and notice obligations on top of that authorization: FDA‑recognized donor questionnaires, informed consent, written notice about testing and potential deferral, and a mandatory RN screening. It creates a narrow legal route for disclosure of reactive HIV results to local health officers when the center cannot locate a donor, plus an expunge‑after‑notification requirement to limit long‑term retention of identifying material obtained through that process. It also provides a limited statutory shield against liability for inadvertent HIV test disclosures by public entities or centers.
Staffing, scope of practice, testing exemptions, and adult consent
Operators may rely on a mix of licensed and properly trained unlicensed staff for predonation screening and for blood collection tasks, provided work review and supervision requirements are met and align with federal GMP rules. The bill permits delegation so the physician need not be on site, but keeps ultimate responsibility with the physician. It also creates a narrow clinical exemption allowing performance of a single total‑protein test by center staff using a digital refractometer without clinical‑lab licensure, and confirms adults 18+ may consent to paid donations.
Licensing mechanics, timelines, inspection powers, and penalties
The Department must prescribe an application form with specific content; if it does not issue a written refusal within 60 days, the application is deemed approved. License amendments and renewals are subject to departmental fees (capped by reasonableness rules tied to administrative costs) and deposit to the Clinical Laboratory Improvement Fund. The Department gains routine inspection and evidence‑collection powers, and may suspend or revoke licenses following established administrative procedures. Violations are misdemeanors with fines ($100–$1,000) or jail (up to 30 days), and the Department may adopt implementing regulations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Commercial plasma operators and collectors — The bill creates a predictable, state‑level licensing path, explicitly permits donor compensation, and authorizes a broader set of personnel to perform collection tasks, lowering operational uncertainty for new and expanding centers.
- Plasma‑derived product manufacturers — A clearer in‑state regulatory framework and authorized paid collections could expand local supply chains for source material used in therapeutics and biologics manufacturing.
- Adult donors who choose payment — The statute affirms adult consent at 18 and adds standardized informed‑consent and testing notices, which creates clearer expectations for paid donors about risks and deferral consequences.
- Department of Public Health (administratively) — The bill centralizes regulatory authority over source plasma centers in one state agency, giving it rulemaking and inspection tools to oversee these facilities and to set licensing fees to cover program costs.
Who Bears the Cost
- State Department of Public Health — The department assumes licensing, inspection, enforcement, and rulemaking duties that expand its workload; although fees are intended to cover costs, actual program funding depends on legislative appropriation and fee‑setting adequacy.
- Local health officers — They must accept disclosures of reactive HIV results when centers cannot locate donors and then conduct notification efforts and expunge records afterward, adding investigative and records‑management responsibilities.
- Small or new operators — Compliance costs (application, recurring fees, required medical director, training, recordkeeping, and potential modifications to facilities and SOPs to meet FDA and state standards) could be significant relative to margins.
- Existing blood banks and transfusion services — The statutory distinction and exemptions could create market pressure and require adjustments in partnerships, referral practices, or compliance programs if centers operate under a different statutory regime.
Key Issues
The Core Tension
The bill balances two legitimate but conflicting aims: expanding and stabilizing plasma supplies by permitting paid collection and easing operational constraints, versus minimizing public‑health and privacy risks through oversight and donor protections; the more access and flexibility the statute grants operators, the greater the burden on regulators and local health officials to police safety, notification, and confidential handling of infectious‑disease test results.
The bill resolves several practical questions but leaves important ambiguities that will drive implementation disputes. ‘Reasonable efforts’ by centers to locate donors before disclosing reactive HIV results is undefined, creating potential disagreements between centers and local health officers about when disclosure is permitted. The expungement requirement for health officers ties public‑health investigatory duties to a data‑destruction obligation without specifying retention windows, audit trails, or exceptions for public‑health surveillance, raising legal and operational questions about record integrity and disease surveillance continuity.
Federal overlap is another unresolved area. The statute references FDA‑recognized donor questionnaires, GMP review, and CLIA classifications, yet creates state exemptions and a specific testing exemption for a digital refractometer; aligning state rules with federal requirements and accreditor expectations will require careful regulation.
The 60‑day deemed‑approval rule for licenses accelerates entry but risks creating compliance pitfalls if the Department lacks resources to vet applications; operators could begin work under an issued license before regulations or inspection capacity are fully in place. Finally, the bill’s misdemeanor enforcement (low fines and short jail exposure) may not match the public‑health stakes of serious compliance failures, leaving regulators reliant on administrative license action rather than criminal deterrence.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.